Literature DB >> 29224970

Management of conjunctival perforation and late Seidel after XEN® surgery.

Á Olate-Pérez1, V T Pérez-Torregrosa2, A Gargallo-Benedicto2, R Escudero-Igualada2, M Cerdà-Ibáñez2, A Barreiro-Rego2, A Duch-Samper2.   

Abstract

CLINICAL CASE: The case concerns a 78 year-old woman with a history of XEN® surgery, in whom a conjunctival perforation was observed at the implant level at 18-months of follow-up, for which surgical intervention was decided. During surgery a short subconjunctival portion was found (0.5mm). An unsuccessful attempt was made to extract it by traction, but the XEN® broke easily. Finally, it was decided to cut it to scleral level, and suture the conjunctiva. During the first week there was a decrease in intraocular pressure (6mmHg), to subsequently increase to 25, and deciding to start medical treatment. DISCUSSION: Conjunctival exposure of the XEN® stent is a rare but potentially serious complication. To avoid it, a meticulous surgical technique is important when implanting it. If this occurs, it is important to identify the cause. If it is due to a short subconjunctival portion, a therapeutic alternative is to cut the implant at this level to avoid further complications.
Copyright © 2017 Sociedad Española de Oftalmología. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Collagen; Colágeno; Glaucoma; Microcirugía; Microsurgery; XEN(®) gel stent; XEN(®)gel stent

Mesh:

Year:  2017        PMID: 29224970     DOI: 10.1016/j.oftal.2017.10.002

Source DB:  PubMed          Journal:  Arch Soc Esp Oftalmol (Engl Ed)        ISSN: 2173-5794


  3 in total

1.  [MIGS-off-label option for treatment-refractory steroid-induced ocular hypertension].

Authors:  Bettina Hohberger; Marius Haug; Antonio Bergua; Robert Lämmer
Journal:  Ophthalmologe       Date:  2020-01       Impact factor: 1.059

2.  Postoperative complications of Ab-Interno XEN implantation in primary angle closure glaucoma.

Authors:  Samuel Asanad; Sachin Kalarn; Mona A Kaleem
Journal:  Am J Clin Exp Immunol       Date:  2021-02-15

3.  PreserFlo MicroShunt® exposure: a case series.

Authors:  Roxane Bunod; Mathieu Robin; Juliette Buffault; Chafik Keilani; Antoine Labbé; Christophe Baudouin
Journal:  BMC Ophthalmol       Date:  2021-07-10       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.